Frank P. Zemlan

Frank P. Zemlan

Vorstandsvorsitzender bei Phase 2 Discovery, Inc.

4 Beziehungen
Health Technology
Consumer Services

Aktive Positionen von Frank P. Zemlan

UnternehmenPositionBeginnEnde
Phase 2 Discovery, Inc.
Logo Phase 2 Discovery, Inc.

Phase 2 Discovery, Inc.

Pharmaceuticals: MajorHealth Technology

Phase 2 Discovery, Inc. (P2D) develops central nervous system drugs. The company provides discovery research & development services for pharmaceutical and biotechnology companies. It also develops drugs for treating psychiatric and neurologic disorders. Its products include PD6735, the treatment of primary insomnia and additional indications, N-Substituted Analogs of Benztropine for the treatment of attention deficit hyperactivity disorder & Thiothalidomides and Hydroxythalidomides for the treatment of ALS and MS. Phase 2 Discovery was founded in 1998 and is headquartered in Cincinnati, OH.

 Vorstandsvorsitzender - -

Karriereverlauf von Frank P. Zemlan

Ehemalige bekannte Positionen von Frank P. Zemlan

UnternehmenPositionBeginnEnde
Aventis, Inc. Corporate Officer/Principal - -
GSK PLC Corporate Officer/Principal - -
MERCK & CO., INC. Corporate Officer/Principal - -

Ausbildung von Frank P. Zemlan

Villanova University Graduate Degree
University of Pennsylvania Doctorate Degree

Statistik

International

Vereinigte Staaten 6
Vereinigtes Königreich 2

Operativ

Corporate Officer/Principal 3
Chief Executive Officer 1
Graduate Degree 1

Sektoral

Health Technology 4
Consumer Services 3

Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Unternehmensverbindungen

Börsennotierte Unternehmen2
MERCK & CO., INC.

Health Technology

GSK PLC

Health Technology

Private Unternehmen2
Phase 2 Discovery, Inc.
Logo Phase 2 Discovery, Inc.

Phase 2 Discovery, Inc.

Pharmaceuticals: MajorHealth Technology

Phase 2 Discovery, Inc. (P2D) develops central nervous system drugs. The company provides discovery research & development services for pharmaceutical and biotechnology companies. It also develops drugs for treating psychiatric and neurologic disorders. Its products include PD6735, the treatment of primary insomnia and additional indications, N-Substituted Analogs of Benztropine for the treatment of attention deficit hyperactivity disorder & Thiothalidomides and Hydroxythalidomides for the treatment of ALS and MS. Phase 2 Discovery was founded in 1998 and is headquartered in Cincinnati, OH.

Health Technology

Aventis, Inc.

Sehen Sie sich die Unternehmensverbindungen an
  1. Börse
  2. Insiders
  3. Frank P. Zemlan
  4. Erfahrung